The Gross Margin of Decibel Therapeutics Inc (DBTX) is
7775.20%.
Gross Margin represents the percentage of revenue that exceeds the cost of goods sold. It reflects a company's efficiency in producing and selling its products.
| Date |
Value |
| 2022-12-31 |
7775.20%
|
| Ticker |
Name |
Value |
|
NCNA
|
NuCana PLC
|
7775.20%
|
|
ONCR
|
Oncorus Inc
|
7775.20%
|
|
TRVN
|
Trevena Inc
|
46.56%
|
|
IBIO
|
iBio Inc
|
38.40%
|
|
ABUS
|
Arbutus Biopharma Corp
|
7775.20%
|
|
AMGN
|
Amgen Inc
|
70.78%
|
|
CRDF
|
Cardiff Oncology, Inc.
|
100.00%
|
|
LCTX
|
Lineage Cell Therapeutics Inc
|
92.50%
|
|
PRQR
|
ProQR Therapeutics NV
|
7775.20%
|
|
UBX
|
Unity Biotechnology Inc
|
7775.20%
|
|
ABBV
|
AbbVie Inc.
|
71.62%
|
|
CBMG
|
Cellular Biomedicine Group Inc
|
81.65%
|
|
FBRX
|
Forte Biosciences, Inc.
|
7775.20%
|
|
VTGN
|
Vistagen Therapeutics, Inc.
|
7775.20%
|
|
950220.KQ
|
Neoimmunetech Inc
|
7775.20%
|
|
IMNM
|
Immunome, Inc.
|
7775.20%
|
|
REGN
|
Regeneron Pharmaceuticals, Inc.
|
86.56%
|
|
VRTX
|
Vertex Pharmaceuticals Incorporated
|
86.24%
|
|
EIGR
|
Eiger BioPharmaceuticals Inc
|
99.90%
|
|
SNSE
|
Sensei Biotherapeutics Inc
|
7775.20%
|
|
BLU.TO
|
BELLUS Health Inc
|
7775.20%
|
|
AGLE
|
Aeglea Bio Therapeutics Inc
|
7775.20%
|
|
APS.TO
|
Aptose Biosciences Inc
|
100.00%
|
|
CUE
|
Cue Biopharma, Inc.
|
7775.20%
|
|
GILD
|
Gilead Sciences, Inc.
|
78.84%
|
|
OCX
|
OncoCyte Corp
|
39.34%
|
|
950160.KQ
|
Kolon TissueGene Inc
|
13.28%
|
|
IMUX
|
Immunic, Inc.
|
7775.20%
|
|
KZR
|
Kezar Life Sciences, Inc.
|
7775.20%
|
|
MRNA
|
Moderna, Inc.
|
70.32%
|
|
ONCT
|
Oncternal Therapeutics Inc
|
91.24%
|
|
950200.KQ
|
Psomagen Inc
|
24.48%
|
|
VINC
|
Vincerx Pharma Inc
|
7775.20%
|
|
GRTX
|
Galera Therapeutics Inc
|
7775.20%
|